Insulet Corporation (NASDAQ:PODD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Insulet Corporation (NASDAQ:PODD) have been assigned a consensus rating of “Moderate Buy” from the twenty-four analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and nineteen have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $344.3333.

Several equities analysts have recently issued reports on the company. Citigroup lowered Insulet from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $338.00 to $230.00 in a research report on Tuesday. Raymond James Financial decreased their price objective on Insulet from $385.00 to $355.00 and set an “outperform” rating for the company in a research report on Thursday, February 19th. Leerink Partners decreased their price objective on Insulet from $386.00 to $360.00 and set an “outperform” rating for the company in a research report on Thursday, February 19th. Evercore decreased their price objective on Insulet from $340.00 to $240.00 and set an “outperform” rating for the company in a research report on Monday. Finally, Stifel Nicolaus decreased their price objective on Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th.

Insider Activity

In other news, Director Michael R. Minogue purchased 2,030 shares of Insulet stock in a transaction on Wednesday, February 25th. The stock was purchased at an average price of $246.23 per share, with a total value of $499,846.90. Following the transaction, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. The trade was a 13.14% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.39% of the company’s stock.

Hedge Funds Weigh In On Insulet

Large investors have recently bought and sold shares of the company. Larson Financial Group LLC boosted its position in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in Insulet during the 4th quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new position in Insulet during the 4th quarter worth approximately $28,000. DV Equities LLC acquired a new position in Insulet during the 4th quarter worth approximately $28,000. Finally, MV Capital Management Inc. acquired a new position in Insulet during the 4th quarter worth approximately $29,000.

Insulet Price Performance

Insulet stock opened at $202.46 on Wednesday. The firm has a market capitalization of $14.25 billion, a P/E ratio of 57.85, a PEG ratio of 1.22 and a beta of 1.47. Insulet has a 1 year low of $198.10 and a 1 year high of $354.88. The business has a 50-day moving average of $235.63 and a 200-day moving average of $281.99. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.07. The company had revenue of $783.80 million during the quarter, compared to analyst estimates of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.15 EPS. On average, equities analysts anticipate that Insulet will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.